DIESE MELDUNG PER E-MAIL VERSENDEN
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
*
marks required fields
Name des Empfängers:
*
E-Mail des Empfängers:
Nachricht:
*
Enter security words: